(CercleFinance.com) – Innate Pharma announces that five abstracts concerning its drug candidates have been selected for the annual congress of ASCO (American Society of Clinical Oncology), which will be held from May 31 to June 4 in Chicago, United States. -United.
One poster will present the final data from the phase 2 TELLOMAK trial in mycosis fungoides confirming the promising clinical activity of lacutamab, while two others will concern IPH6501 for the treatment of non-Hodgkin B lymphomas.
Two other posters, presented by its partner AstraZeneca, will focus on phase 2 trials with monalizumab in non-operable stage III non-small cell lung cancer and in small cell lung cancer.
Copyright © 2024 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends using the buttons below.
